November 25, 2022: We appreciate the FDA’s interest in establishing requirements for a nonprescription drug product with an additional condition for nonprescription use (ACNU). However, the FDA has not identified a mechanism to ensure appropriate use. Based on our experience with patients across the country, we believe it would be impossible to do so. For that reason, we do not support the proposed ruling.
Read More »Author: Caroline Bradford
National Center for Health Research Comment on Proposed Labeling Recommendations for Patients Considering LASIK
November 25, 2022: NCHR does not support nonbinding FDA LASIK guidance saying it is not enforceable and does not protect patients. We strongly urge the FDA to require patients to be provided with short, easy-to-understand labeling prior to scheduling surgery, and that the FDA improve their example of a LASIK Patient Checklist to provide more balanced information about risks.
Read More »Long COVID National Conference Agenda
Monday, October 3rd, 2022 9:00 am to 9:15 am Welcome from Dr. Diana Zuckerman, President of National Center for Health Research, and Dr. Monica Verduzco-Gutierrez, Chair of Rehabilitation Medicine at Long School of Medicine at UT Health Science Center 9:15 am to 10:15 am Panel I: Autoimmunity and Long COVID: Dr. Rasika Karnik, Assistant […]
Read More »National Center for Health Research National Long COVID Conference on October 3, 2022
October 3, 2022: NCHR’s National Long COVID conference was held in Washington, DC. Topics included autoimmunity, ME/CFS, Caregiving, Children and Teens, Dept of Veterans Affairs, and Research.
Read More »NCHR criticism of drug for chronic kidney disease at FDA Advisory Committee Meeting
November 16, 2022: Elevated phosphorus is a serious complication encountered by the majority of patients with chronic kidney disease on dialysis. Tenapanor represents a novel approach to this major problem. Still, we are concerned about this product because the data do not show it to be more effective than current options, and the significant side effects may lead to poor patient compliance.
Read More »